Skip to main content

IMMP

Stock
Health Care
Biotechnology

Performance overview

IMMP Price
Price Chart

Forward-looking statistics

Beta
0.74
Risk
61.63%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Company info

SectorHealth Care
IndustryBiotechnology
Employees46
Market cap$320.4M

Fundamentals

Enterprise value$1.5B
Revenue$3.2M
Revenue per employee
Profit margin0.00%
Debt to equity0.98

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.21
Dividend per share
Revenue per share$0.04
Avg trading volume (30 day)$176K
Avg trading volume (10 day)$175K
Put-call ratio

Macro factor sensitivity

Growth+0.6
Credit+5.2
Liquidity+2.5
Inflation-1.8
Commodities-0.2
Interest Rates-0.9

Valuation

Dividend yield0.00%
PEG Ratio-6.30
Price to sales50.78
P/E Ratio-6.30
Enterprise Value to Revenue457.00
Price to book14.42

Upcoming events

Next earnings daySeptember 1, 2021
Next dividend day
Ex. dividend day

News

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited IMMP on Thursday announced additional data from the investigator-initiated INSIGHT-003 trial evaluating a triple combination therapy in front-line non-small cell lung cancer patients consisting of efti administered in conjunction with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy (carboplatin and pemetrexed).

Benzinga (May 15, 2025)
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.

Zacks Investment Research (July 15, 2024)
Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer (IMMP)

Immutep jumped as much as 13% to two-week highs on Thursday after the biotechnology company announced that its lead drug candidate for recurrent or metastatic head and neck cancer has received a fast track status from the US Food and Drug Administration. Immutep was up 8% to $3.45 as of 12:00 p.m. ET, having risen to a session peak of $3.59 earlier in the day, its highest since March 25.

Business Insider (April 8, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free